Navigation Links
PharmaNet Development Group Announces Observational Research Survey
Date:10/11/2010

PRINCETON, N.J., Oct. 11 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries announced today the availability of a new survey on pharmaceutical Observational Research, the fourth in an on-going series. The survey is open to all in the industry with an interest in observational research and can be accessed here through October 31, 2010.  

Jeff Trotter,  Executive Vice President, Phase IV Development, and creator of the survey, remarked, "Pharmaceutical companies are increasingly looking to prospective Observational Research for compiling real world data on post-approval clinical performance, economic value, patient quality-of-life, and product safety. While the scientific community excels at designing and executing controlled clinical trials, there may be less appreciation for the value of observational studies. The goal of the survey is to identify underlying issues in order to move toward more appropriately-designed studies that improve the understanding of product performance among clients, regulators, policymakers, physicians and patients."

Previous surveys have revealed that drug development organizations can benefit from broader cross-functional collaboration and consensus on the strategy for observational research. The latest survey will continue to track evolving trends.

The results of this survey, plus the findings identified in previous surveys, are expected to be released in November.  If you are interested in receiving the findings report or receiving more information on pharmaceutical observational research, please contact aserody@pharmanet.com.  

About PharmaNet Development Group, Inc.PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2300 employees in 33 countries and more than 38 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.  Contact: Anne-Marie HessPhone:   (609) 951-6842E-mail:   ahess@pharmanet.com
'/>"/>

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009
2. Azopharma and PharmaNet Development Group Enter Preclinical Strategic Alliance
3. PharmaNet Development Group Management Participates in the 8th Annual Partnerships in Clinical Trials Conference in Rotterdam
4. Jeffrey Trotter Joins Pharmanet Development Group as Executive Vice President, Phase IV Development
5. Steven Leventer Joins PharmaNet Development Group as Vice President, Clinical Research Neuroscience
6. PharmaNet Development Group Symposia Crossing the Bridge from Preclinical to Clinical Studies to be Held February 2010 in Basel, Dusseldorf and Vienna
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. Promising Cystic Fibrosis Compound on Track for Development
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2017)... BELL, Pa. , June 1, 2017 ... (PRN) and Veterinarian Recommended Solutions (VRS), and KD Pharma ... investment in Nutriceutical Holdings by KD Pharma Group. KD ... Holdings with the option to acquire the entire company. ... partner in KD. They are committed to growing the ...
(Date:5/30/2017)... 2017 Therapix Biosciences Ltd. (Nasdaq: TRPX), ... the development of cannabinoid-based drugs, today announced that ... at three upcoming scientific and investor conferences in ... Invitational: ...                     Wednesday, June ...
(Date:5/26/2017)... May 25, 2017  In response to the opioid ... Direct Relief is working with Pfizer to make up ... no cost to community health centers, free and charitable ... "Pfizer has a long-standing commitment to ... ensuring patient safety through educational activities," said Caroline ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. ... New York, has recently begun offering three new minimally invasive procedures to patients ... procedures and reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has recently highlighted Dr. ... come up with a proprietary technique that he calls the AuraLyft Facelift. ... For all ages, patients can expect to look refreshed, rejuvenated, and revitalized. , ...
(Date:6/23/2017)... ... June 23, 2017 , ... MD Now Urgent Care opened its ... facility overall and marks the urgent care center's eighth location in Miami-Dade county. , ... Falls shopping mall. The new clinic offers a wide array of services ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ulster University, Magee Campus in ... 9 am to 3 pm to present to graduate students exciting new and innovative ... original curriculum project led by The Health Improvement Service of the Western Health & ...
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, ... families and business owners in North Central West Virginia, is embarking on a ... differently abled residents in the region. , The Stepping Stones organization offers a ...
Breaking Medicine News(10 mins):